Month: September 2025

SHANGHAI, Sept. 26, 2025 (GLOBE NEWSWIRE) — Fangzhou Inc. (“Fangzhou” or the “Company”) (06086.HK), a leader in AI-driven Internet healthcare solutions, announced that its “XingShi” Large Language Model (“XS LLM”) was featured by Nature News under the headline “A Chinese AI tool can manage chronic disease — could it revolutionize health care?” The article, written by science reporter Mohana Basu, cited the model’s potential applications for chronic disease management, while citing expert commentary. Xinhua News Agency also highlighted the piece under the headline “Nature focuses on Fangzhou’s XS LLM: Chinese AI tackling global chronic disease challenges.” This recognition underscores the growing role of AI in addressing global health issues. Fangzhou’s XS LLM, released in September, was designed to address...

(Oslo/Bergen 26 September 2025) Statkraft and Eviny have signed an agreement with Nepalese local partner Butwal Power Company (BPC) to sell their 57 and 26 percent shareholdings in Himal Power Limited (HPL). With this transaction, BPC will own 100 percent of the shares in HPL.  HPL owns the 60 MW Khimti I Hydropower Plant which started operations in 2000. This initiative is consistent with Statkraft’s strategy of exiting South Asia and focusing on key markets in Europe and South America. The construction of the Khimti I Hydropower Plant in Nepal was Statkraft’s first hydropower development outside Norway.  “Statkraft and Eviny are proud of the important contribution the Khimti plant has made to the Nepalese energy system for 25 years, delivering more than 9,000 GWh of energy with an excellent operational record and world class availability....

Reserve Bank of India (RBI) has approved biometric authentication technology for digital payments, including IDEX’s fingerprint payment solutions, through new authentication mechanisms for digital payment transactions directions effective April 2026. The RBI mandate specifically endorses fingerprint biometric authentication as an approved method for India’s digital payment ecosystem, moving beyond traditional SMS-based one-time passwords. This regulatory approval validates IDEX’s strategic positioning in the Indian market. Anders Storbråten, CEO of IDEX Biometrics, highlighted the strategic significance: “The RBI’s approval of biometric authentication represents a transformational moment for digital payment security in India. IDEX has been strategically positioned for this regulatory shift, having successfully...

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products are manufactured from U.S. donors in the U.S. and designated as U.S. origin products not subject to tariffs on imported branded or patented pharmaceutical products. Ryoncil® (remestemcel-L) is the only allogeneic mesenchymal stromal cell therapy approved by U.S. Food and Drug Administration (FDA) for any indication. As documented in the Company’s Biologic License Application (BLA), Ryoncil® is designated a ‘U.S. Country of Origin’ product in line with U.S. FDA and Customs regulatory guidance. Ryoncil® is approved for treatment of pediatric patients 2 months and older, including adolescents and teenagers, with steroid-refractory...

Key data from PSMAddition has been selected for a Presidential session; data to showcase the efficacy and safety of PluvictoTM plus standard of care (SoC) versus SoC alone in PSMA+ mHSPCNATALEE five-year analysis of Kisqali® to provide further long-term insights into risk of recurrence reduction in a broad EBC patient populationNew data for Pluvicto in prostate cancer and Kisqali in breast cancer strengthen the profiles of both medicines, with promise for new SoC in earlier disease settingsBasel, September 26, 2025 – Novartis will present new data from 34 abstracts across its oncology portfolio at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin (October 17-21, 2025). “We look forward to sharing new clinical data that underscores how we are reimagining treatment for breast and prostate cancer, advancing...

Oslo, 26 September 2025 – DNO ASA, the Norwegian oil and gas operator, today announced that it has been instructed to prepare for commencement of oil exports through the Iraq-Türkiye Pipeline on 27 September 2025, following agreements reached between the Federal Government of Iraq, the Kurdistan Regional Government and a group of international oil companies. DNO accordingly will deliver the Kurdistan Regional Government’s share of sales from the Company’s operated Tawke license, currently averaging 38,000 barrels a day, for export. The balance of the oil, representing the share of sales the foreign contractor group consisting of DNO and Genel Energy International Limited, currently averaging 30,000 barrels a day, will continue to be sold to local buyers under existing contracts. “DNO is pleased that exports of oil from the Kurdistan...

Geneva, Switzerland, September 26, 2025 – Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today announced that it will report its Half-Year and Second Quarter 2025 Financial Results on September 30, 2025 and host a conference call to discuss the results on October 1, 2025. Tim Dyer, CEO and Mikhail Kalinichev, Head of Translational Science, will provide a business update and review of the Addex product pipeline during a teleconference and webcast for investors, analysts and media at 16:00 CEST (15:00 BST / 10:00 EDT / 07:00 PDT) on October 1, 2025. Title:   Addex Therapeutics Reports Half-Year 2025 Financial Results and Provides Corporate UpdateDate: October 1, 2025Time: 16:00 CEST (15:00 BST...

OSE Immunotherapeutics, Inserm Transfert and Nantes University Announce Strategic Partnership to Accelerate Innovation in ImmunotherapyNANTES, France – September 26, 2025, 7:00 a.m. – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), Inserm Transfert (on behalf of Inserm, a French public organization dedicated to human health), and Nantes University today announce the signing of a strategic partnership agreement aimed at accelerating the development of innovative projects in the fields of immunotherapy for oncology, inflammation, and autoimmunity. By combining academic research with industrial expertise, the partnership seeks to transform cutting-edge immunology discoveries into industrial programs capable of delivering breakthrough therapies to patients. This large-scale public–private alliance strengthens long-standing ties...

Wereldhave has signed a partnership with Ocean Outdoor Netherlands as its exclusive media partner to install and operate over 150 new digital advertising screens across 11 shopping and Full Service Centers in the Netherlands. Building on their existing collaboration on large-format video walls, Wereldhave selected Ocean Outdoor for its distinctive approach and innovative vision for the project. The new digital screen network, launching early 2026, will enhance the customer experience while offering tenants, brands and media agencies a high-impact platform to reach millions of consumers. The partnership is expected to have a positive annualized impact on Wereldhave’s Direct Result Per Share (DRPS) of at least € 0.03. Matthijs Storm, CEO of Wereldhave said: “With nearly 69 million annual visitors, our Dutch centers offer a uniquely valuable...

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) — Cipher Mining Inc. (NASDAQ:CIFR) (“Cipher” or the “Company”), a leading developer and operator of industrial-scale data centers, today announced the pricing of its offering of $1.1 billion aggregate principal amount of 0.00% convertible senior notes due 2031 (the “notes”) in a private offering (the “offering”) to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offering size was increased from the previously announced offering size of $800 million aggregate principal amount of notes. The issuance and sale of the notes are scheduled to settle on September 30, 2025, subject to customary closing conditions. Cipher granted the initial purchasers of the notes a 13-day option to purchase...